Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer.
Hitomi SakaiHiasto KawakamiTakeshi TeramuraYuta OnoderaElizabeth SomersKeiji FuruuchiToshimitsu UenakaRyoji KatoKazuhiko NakagawaPublished in: Clinical and translational medicine (2022)
The ADC could be a more reasonable choice than mAb as a targeting agent for the FOLRα-expressing tumor.